These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 10197049

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tacrolimus: a review of its use for the management of dermatoses.
    Gupta AK, Adamiak A, Chow M.
    J Eur Acad Dermatol Venereol; 2002 Mar; 16(2):100-14. PubMed ID: 12046809
    [Abstract] [Full Text] [Related]

  • 23. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology.
    Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner FJ, Winiski A, Wolff B, Zenke G.
    Br J Dermatol; 1999 Aug; 141(2):264-73. PubMed ID: 10468798
    [Abstract] [Full Text] [Related]

  • 24. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models.
    Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, Hsieh GC, Luly JR.
    Toxicology; 1998 Feb 06; 125(2-3):169-81. PubMed ID: 9570331
    [Abstract] [Full Text] [Related]

  • 25. Systemic ciclosporin and tacrolimus in dermatology.
    Madan V, Griffiths CE.
    Dermatol Ther; 2007 Feb 06; 20(4):239-50. PubMed ID: 17970889
    [Abstract] [Full Text] [Related]

  • 26. Potential new indications of topical calcineurin inhibitors.
    Luger T, Paul C.
    Dermatology; 2007 Feb 06; 215 Suppl 1():45-54. PubMed ID: 18174692
    [Abstract] [Full Text] [Related]

  • 27. Novel immunomodulators for topical skin disease therapy.
    Travers JB.
    Expert Opin Investig Drugs; 2000 Mar 06; 9(3):529-42. PubMed ID: 11060693
    [Abstract] [Full Text] [Related]

  • 28. [Topical corticosteroids versus topical inhibitors of calcineurin].
    Niedner R.
    Hautarzt; 2003 Apr 06; 54(4):338-41. PubMed ID: 12669205
    [Abstract] [Full Text] [Related]

  • 29. Pimecrolimus in dermatology: atopic dermatitis and beyond.
    Gisondi P, Ellis CN, Girolomoni G.
    Int J Clin Pract; 2005 Aug 06; 59(8):969-74. PubMed ID: 16033622
    [Abstract] [Full Text] [Related]

  • 30. Tacrolimus in dermatology.
    Dé Tran QH, Guay E, Chartier S, Tousignant J.
    J Cutan Med Surg; 2001 Aug 06; 5(4):329-35. PubMed ID: 11907845
    [Abstract] [Full Text] [Related]

  • 31. Tacrolimus: the drug for the turn of the millennium?
    Ruzicka T, Assmann T, Homey B.
    Arch Dermatol; 1999 May 06; 135(5):574-80. PubMed ID: 10328199
    [Abstract] [Full Text] [Related]

  • 32. Tacrolimus ointment for the treatment of atopic dermatitis: clinical and pharmacologic effects.
    Rico MJ, Lawrence I.
    Allergy Asthma Proc; 2002 May 06; 23(3):191-7. PubMed ID: 12125507
    [Abstract] [Full Text] [Related]

  • 33. Topical tacrolimus.
    Frankel SJ, Kerdel FA.
    Skin Therapy Lett; 2001 May 06; 6(4):1-2, 5. PubMed ID: 11176043
    [Abstract] [Full Text] [Related]

  • 34. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis.
    Trautmann A, Akdis M, Schmid-Grendelmeier P, Disch R, Bröcker EB, Blaser K, Akdis CA.
    J Allergy Clin Immunol; 2001 Nov 06; 108(5):839-46. PubMed ID: 11692113
    [Abstract] [Full Text] [Related]

  • 35. [Tacrolimus in diseases other than atopic dermatitis].
    Alomar A, Corella F, García-Navarro X.
    Actas Dermosifiliogr; 2008 Feb 06; 99 Suppl 2():26-35. PubMed ID: 18346427
    [Abstract] [Full Text] [Related]

  • 36. Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity.
    Geba GP, Ptak W, Askenase PW.
    Immunology; 2001 Oct 06; 104(2):235-42. PubMed ID: 11683964
    [Abstract] [Full Text] [Related]

  • 37. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis.
    Guttman-Yassky E, Ungar B, Malik K, Dickstein D, Suprun M, Estrada YD, Xu H, Peng X, Oliva M, Todd D, Labuda T, Suarez-Farinas M, Bissonnette R.
    J Allergy Clin Immunol; 2017 Oct 06; 140(4):1032-1042.e13. PubMed ID: 28238742
    [Abstract] [Full Text] [Related]

  • 38. Topical tacrolimus and pimecrolimus: future directions.
    Ling MR.
    Semin Cutan Med Surg; 2001 Dec 06; 20(4):268-74. PubMed ID: 11770914
    [Abstract] [Full Text] [Related]

  • 39. Safety of the new macrolide immunomodulators.
    Robinson N, Singri P, Gordon KB.
    Semin Cutan Med Surg; 2001 Dec 06; 20(4):242-9. PubMed ID: 11770911
    [Abstract] [Full Text] [Related]

  • 40. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
    Wolff K.
    Skin Therapy Lett; 2005 Oct 06; 10(8):1-6. PubMed ID: 16292456
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.